A special protein can play a key role in the fight against certain types of prostate cancer. This is shown in a study by an international research group led from Umeå University, Sweden. Until now, treatments have involved blocking the protein in question that builds a so-called signalling pathway, but now the researchers show that by instead doing the opposite and activating the protein and signalling pathway, the cancer is counteracted.
“Our results show that by activating the signaling pathway, not only does the growth of the tumour be slowed down, but the immune system is then stimulated to actively fight tumour cells,” says Lukas Kenner, visiting professor at the Department of Molecular Biology at Umeå University.
The protein in question is called glycoprotein 130, GP130. It acts as a receptor on the surface of cells. When the GP130 is activated, it sends signals inside the cell via a chain of events, a signaling pathway, that controls how certain genes are expressed.
A special molecule that is activated by this signaling pathway is called STAT3. It is a so-called transcription factor; It acts as a switch that turns genes on or off, and it thus affects how the cell behaves. The STAT3 molecule plays a critical role in the development and spread of tumor cells. Consequently, research has hypothesized that blocking GP130, thereby disrupting the associated signaling pathway, would inhibit STAT3 activity and, in turn, suppress cancer growth.
Surprisingly, the current study shows the exact opposite. The researchers instead activated GP130 and with it the signaling pathway in the prostate of genetically modified mice. They could then see that the result was that the growth of the tumour was clearly slowed down in the mice due to the activation of Stat3. Studies of tissue samples from prostate cancer patients also supported these results. There it was possible to see that those high levels of GP130 positively correlated with better survival.
“In the long term, this opens up the possibility for a promising new treatment option for mainly certain forms of aggressive prostate cancer that are currently difficult to treat,” says Lukas Kenner.
The researchers are now proceeding with more studies to be able to confirm the results. More research is needed before we can test the method in studies on patients. The study has been led by Lukas Kenner, visiting professor at Umeå University, together with Stefan Rose-John, at the University of Kiel, Germany. The Swedish part of the research group has also been led by Jenny Persson, professor at the Department of Molecular Biology at Umeå University.